Clinical features and laboratory findings of human parvovirus B19 in human immunodeficiency virus-infected patients

Mem Inst Oswaldo Cruz. 2014 Apr;109(2):168-73. doi: 10.1590/0074-02760130312.

Abstract

Immunocompromised patients may develop severe chronic anaemia when infected by human parvovirus B19 (B19V). However, this is not the case in human immunodeficiency virus (HIV)-infected patients with good adherence to highly active antiretroviral treatment (HAART). In this study, we investigated the clinical evolution of five HIV-infected patients receiving HAART who had B19V infections confirmed by serum polymerase chain reaction. Four of the patients were infected with genotype 1a strains and the remaining patient was infected with a genotype 3b strain. Anaemia was detected in three of the patients, but all patients recovered without requiring immunoglobulin and/or blood transfusions. In all cases, the attending physicians did not suspect the B19V infections. There was no apparent relationship between the infecting genotype and the clinical course. In the HAART era, B19V infections in HIV-positive patients may be limited, subtle or unapparent.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anemia / complications
  • Anemia / diagnosis
  • Antibodies, Viral / blood*
  • Antibodies, Viral / immunology
  • Antiretroviral Therapy, Highly Active
  • Biomarkers / blood
  • CD4 Lymphocyte Count
  • Female
  • Genotype
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • Humans
  • Male
  • Medication Adherence
  • Middle Aged
  • Parvoviridae Infections / complications
  • Parvoviridae Infections / immunology*
  • Parvovirus B19, Human / genetics
  • Parvovirus B19, Human / immunology*
  • Parvovirus B19, Human / isolation & purification*
  • Polymerase Chain Reaction

Substances

  • Antibodies, Viral
  • Biomarkers

Grants and funding

Financial support: CNPq (473432/2010-20)